首页> 外文期刊>Journal of Cancer >A Panel of Four-lncRNA Signature as a Potential Biomarker for Predicting Survival in Clear Cell Renal Cell Carcinoma
【24h】

A Panel of Four-lncRNA Signature as a Potential Biomarker for Predicting Survival in Clear Cell Renal Cell Carcinoma

机译:一种四个LNCRNA签名作为潜在生物标志物,用于预测透明细胞肾细胞癌中存活的潜在生物标志物

获取原文
           

摘要

Long non-coding RNAs (lncRNAs) have been considered as biomarkers for the carcinogenesis and development of various cancers. However, the prognostic significance of lncRNAs in renal cell carcinoma (RCC) remains unclear. This study aimed to determine the predictive ability of lncRNAs in clear cell RCC (ccRCC). Among the cohort of kidney renal clear cell carcinoma (KIRC) of the The Cancer Genome Atlas (TCGA), 525 patients were enrolled in our study. Expression of lncRNAs based on RNAseq was obtained from TCGA. Kaplan-Meier prognostic analysis and a Cox proportional hazards regression model were used to assess related factors. The lncRNA signature was then validated in an independent cohort of an additional 60 ccRCC patients. Hierarchical clustering of the KIRC TCGA dataset identified 26 differentially expressed lncRNAs (11 down-regulated and 15 up-regulated) using average linkage clustering. Kaplan-Meier survival analysis identified 30 statistically significant lncRNAs that strongly predicted prognosis, with 4 ccRCC-specific lncRNAs (TCL6, PVT1, MIR155HG, and HAR1B) being differentially expressed and correlating significantly with OS. Patients assigned to the high-risk group were associated with poor OS compared with patients in the low-risk group (HR = 2.57; 95%CI, 1.89-3.50; p 0.001). This finding was validated in the Tongji Hospital cohort, and the four-lncRNA signature was shown to be significantly predictive of ccRCC prognosis (p 0.001). In this study, we constructed an applicable four-lncRNA-based classifier as a reliable prognostic and predictive tool for OS in patients with ccRCC.? The author(s).
机译:长期非编码RNA(LNCRNA)被认为是致癌和各种癌症发育的生物标志物。然而,LNCRNA在肾细胞癌(RCC)中的预后意义仍不清楚。本研究旨在确定透明细胞RCC(CCRCC)中LNCRNA的预测能力。在癌症基因组地图集(​​TCGA)的肾脏肾透明细胞癌(KIRC)中,我们的研究招生了525名患者。基于RNASEQ的LNCRNA的表达是从TCGA获得的。 Kaplan-Meier预后分析和Cox比例危险回归模型用于评估相关因素。然后在额外的60个CCRCC患者的独立队列中验证了LNCRNA签名。使用平均链接聚类,kIRC TCGA数据集的分层聚类识别26个差异表示的LNCRNA(11个下调和15个上调)。 Kaplan-Meier生存分析确定了30个统计学上显着的LNCRNA,其强烈预测预后,具有4个CCRCC特异性的LNCRNA(TCL6,PVT1,miR155Hg和Har1B)与OS差异显着表达和相关。与低风险组中的患者相比,分配给高风险组的患者与OS差有关(HR = 2.57; 95%CI,1.89-3.50; P <0.001)。这一发现在同济医院队列中验证,并显示了四个LNCRNA签名可显着预测CCRCC预测(P <0.001)。在这项研究中,我们构建了一种适用的四LNCRNA类分类器,作为CCRCC患者的操作系统的可靠预测和预测工具。作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号